Worldwide Prescription Drug Sales to Top Trillion Dollar Mark in 2022 with 32% of the 2022 Increase in Sales to Come From Orphan Drugs

LONDON, BOSTON, SAN FRANCISCO, TOKYO (June 13, 2017) — Life science commercial intelligence firm, Evaluate, is launching their annual complimentary industry report, “EvaluatePharma World Preview 2017, Outlook to 2022” at the annual BIO International Convention in San Diego, June 19-22, 2017, Booth #3627.

The report, which sets the industry standard for consensus forecasts for the life sciences, provides an overview of the sector including key trends, patent expiry impact, top products and companies, R&D spend and consensus forecasts to 2022. Complimentary copies of the executive summary will be available in the Evaluate Booth #3627. Follow @evaluatepharma on Twitter to receive download link for the full report on release date June 20th or visit

The Evaluate team will also showcase key new data sets and analyses designed to support faster and more accurate asset screening, appraisal and forecasting for their clients high value decisions, including:

  • Regional sales forecast coverage expanded for US, Europe and Japan
  • R&D Analyzer – transparent benchmark and drug-specific Probability of Technical and Regulatory Success (PTRS), predictive timeline and R&D cost metrics alongside clinical trial endpoints and outcomes in a single view
  • Epi Analyzer – Epidemiology and patient segmentation analysis for 8,000 sub-populations across 160 indications

In attendance to discuss the report findings and latest analyses will be Anthony Raeside, Head of Research; Antonio Iervolino, Head of Forecasting; Andy Williams, Head of Product Management and Paul Verdin, PhD Head of Custom Services. Staff from the UK, Japan and US offices will also be in attendance. Meetings can be scheduled by going to or through the BIO Partnering system, or simply stop by the Evaluate Booth #3627 where there is a private meeting space.

About Evaluate Ltd.

Evaluate provides trusted commercial intelligence and predictive analytics for the pharmaceutical industry and their advisors.

Our Evaluate Omnium and Evaluate Pharma® platforms offer unique and dynamic insights into pharma asset risk and commercial potential alongside a seamless, comprehensive view of the pharmaceutical market landscape.

Evaluate Vantage – our award-winning, independent editorial team – provides thought-provoking news and insights into current and future industry developments.

Evaluate has been a partner to industry-leading organisations for 25 years. For more information on how we give our clients the time and understanding to drive better decisions, visit

Follow us on Twitter: @EvaluatePharma, @EvaluateVantage

For media inquiries, please contact [email protected].